Serum LDH predicts benefit from bevacizumab beyond progression in metastatic colorectal cancer

被引：0

作者：

Federica Marmorino

Lisa Salvatore

Cecilia Barbara

Giacomo Allegrini

Lorenzo Antonuzzo

Gianluca Masi

Fotios Loupakis

Beatrice Borelli

Silvana Chiara

Maria Chiara Banzi

Emanuela Miraglio

Domenico Amoroso

Francesco Dargenio

Andrea Bonetti

Angelo Martignetti

Myriam Paris

Daniela Tomcikova

Luca Boni

Alfredo Falcone

Chiara Cremolini

机构：

[1] Azienda Ospedaliero-Universitaria Pisana,Department of Medical Oncology

[2] Ospedale Civile di Livorno,Division of Medical Oncology

[3] Pontedera Hospital,Department of Oncology

[4] Azienda Ospedaliero-Universitaria Careggi,undefined

[5] Istituto Oncologico Venoto,undefined

[6] National Institute for Cancer Research,undefined

[7] Arcispedale Santa Maria Nuova,undefined

[8] IRCCS,undefined

[9] S. Croce General Hospital,undefined

[10] Ospedale Versilia–Lido di Camaiore,undefined

[11] Dipartimento oncologico AUSL 6 Livorno–Piombino,undefined

[12] Department of Medical Oncology Mater Salutis Hospital Legnago,undefined

[13] Dipartimento Oncologico AUSL 7,undefined

[14] S.O.C. Oncologia–Ospedale degli Infermi,undefined

[15] Fondazione Sandro Pitigliani,undefined

[16] Clinical Trial Coordinating Center,undefined

[17] AOU Careggi,undefined

[18] Istituto Toscano Tumori,undefined

来源：

British Journal of Cancer | 2017年 / 116卷

关键词：

bevacizumab beyond progression; LDH; predictive marker;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：318 / 323

页数：5

共 50 条

[21] IMPACT OF LDH, CEA AND CA 19.9 ON RESPONSE, OVERALL AND PROGRESSION-FREE SURVIVAL IN METASTATIC COLORECTAL CANCER TREATED WITH BEVACIZUMAB
Pissarro, Cristina
Mariano, Monica
Dias, Florbela
Pazos, Isabel
Bonito, Nuno
Ribeiro, Joao
Jacinto, Paula
Gervasio, Helena
ANNALS OF ONCOLOGY, 2012, 23 : 105 - 105
[22] Predicting benefit from FOLFOXIRI plus bevacizumab versus FOLFOX/FOLFIRI plus bevacizumab in patients with metastatic colorectal cancer
Bond, M. J. G.
van Smeden, M.
Degeling, K.
Cremolini, C.
Schmoll, H. J. E-V.
Rossini, D.
Ibach, S.
Koopman, M.
Punt, C. J. A.
May, A. M.
Kwakman, J. J.
ANNALS OF ONCOLOGY, 2023, 34 : S438 - S438
[23] Bevacizumab exposure beyond first disease progression in patients with metastatic colorectal cancer: analyses of the ARIES observational cohort study
Grothey, Axel
Flick, E. Dawn
Cohn, Allen L.
Bekaii-Saab, Tanios S.
Bendell, Johanna C.
Kozloff, Mark
Roach, Nancy
Mun, Yong
Fish, Susan
Hurwitz, Herbert I.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2014, 23 (07) : 726 - 734
[24] CLINICAL OUTCOMES IN BEVACIZUMAB-TREATED PATIENTS WITH METASTATIC COLORECTAL CANCER: RESULTS FROM ARIES OBSERVATIONAL COHORT STUDY AND CONFIRMATION OF BRITE DATA ON BEVACIZUMAB BEYOND PROGRESSION
Cohn, A.
Bekaii-Saab, T.
Bendell, J.
Hurwitz, H.
Kozloff, M.
Roach, N.
Tezcan, H.
Feng, S.
Sing, A.
Grothey, A.
ANNALS OF ONCOLOGY, 2010, 21 : 11 - 11
[25] Bevacizumab Beyond First Progression Is Associated With Prolonged Overall Survival in Metastatic Colorectal Cancer: Results From a Large Observational Cohort Study (BRiTE)
Grothey, Axel
Sugrue, Mary M.
Purdie, David M.
Dong, Wei
Sargent, Daniel
Hedrick, Eric
Kozloff, Mark
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (33) : 5326 - 5334
[26] Bevacizumab beyond progression in breast cancer
Dirix, Luc Y.
Reynolds, Andrew R.
LANCET ONCOLOGY, 2014, 15 (11): : 1190 - 1191
[27] Cetuximab or bevacizumab in metastatic colorectal cancer?
Sclafani, Francesco
Cunningham, David
LANCET ONCOLOGY, 2014, 15 (10): : 1040 - 1041
[28] Spotlight on bevacizumab in metastatic colorectal cancer
Susan, Paul L. McCormack
Keam, Susan J.
BIODRUGS, 2008, 22 (05) : 339 - 341
[29] Bevacizumab Maintenance in Metastatic Colorectal Cancer
Mo, Miao
Yang, Jianing
Zhu, Xiaodong
Zhu, Ji
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (23) : 2451 - +
[30] FOLFOXIRI and bevacizumab in metastatic colorectal cancer
Rahman, Ahmadur
LANCET ONCOLOGY, 2014, 15 (13): : E590 - E590

← 1 2 3 4 5 →